Syncell’s Microscoop Winner of BioTech Breakthrough Award For “Proteomics Solution of the Year”
21 nov. 2024 20h16 HE
|
BioTech Breakthrough
TAIPEI, Taiwan and WATERTOWN, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Syncell, a leader in next-generation subcellular protein purification and spatial proteomics analysis, today announced that...
Bio Usawa and Rwandan Government Sign a Memorandum of Understanding to Manufacture Affordable Biologics in Africa
21 nov. 2024 12h46 HE
|
Bio Usawa Inc
Bio Usawa and the Rwanda Development Board have partnered to establish Rwanda’s first manufacturing plant for affordable treatments for serious eye disease
Bioburden Testing Market Analysis Report 2024-2030: Outsourcing Surge Boosts Bioburden Testing Services as CMOs Expand Globally
21 nov. 2024 10h55 HE
|
Research and Markets
Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Bioburden Testing Market Size, Share and Trends Analysis Report by Product (Consumables, Instruments), Test, Application, End-use, and Region...
Flow Cytometry Market Expected To Reach USD 11553.44 Mn by 2032, Growing at 8.21% CAGR | Introspective Market Research
21 nov. 2024 09h32 HE
|
Introspective Market Research
United States, New York, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Dotmatics, a prominent company in R&D scientific software that integrates science, data, and decision-making, recently finalized the...
Bluejay Therapeutics Announces Expansion of Leadership Team and Board of Directors
21 nov. 2024 09h00 HE
|
Bluejay Therapeutics
SAN MATEO, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a clinical-stage biopharmaceutical company rapidly progressing transformative therapies for viral hepatitis and other...
Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201’s Unique Pulsatile Mechanism of Action
21 nov. 2024 09h00 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that new analyses...
Aclarion Announces Nociscan Featured in RSNA Edition of Siemens MAGNETOM Flash
21 nov. 2024 08h00 HE
|
Aclarion, Inc.
Article Focuses on how Leading Physicians are Incorporating Nociscan Into Their Clinical Practices for Chronic Low Back Pain Patients MAGNETOM Flash is a Peer-to-Peer Magazine Published by Siemens to...
Acies Bio and Protein Evolution Announce Strategic Partnership to Advance Biological Recycling Technology
21 nov. 2024 08h00 HE
|
ACIES BIO d.o.o
Acies Bio and Protein Evolution join forces to produce plastic degradation enzymes developed using advanced Acies Bio microbial strains.l
Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group
21 nov. 2024 05h30 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease
20 nov. 2024 07h30 HE
|
Ocugen
MALVERN, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...